Neurocrine Biosciences revenue and financials
$145.51Change from previous close: +0.90%Absolute change: +$1.30
In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of $2.86B (+21.45% year over year). Net income was $478.6M, a net margin of 16.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 783 | 595 | 390 | 339 | 257 | 229 | 147 | 101 | -94.3 | -106 |
| Depreciation and amortization | 26.0 | 23.5 | 17.8 | 15.1 | 10.9 | 8.6 | 7.4 | 4.0 | 2.4 | 1.5 |
| Capital expenditure | -34.0 | -38.2 | -28.3 | -16.5 | -23.4 | -10.9 | -14.7 | -24.8 | -6.9 | -4.1 |
| Investing cash flow | -264 | -127 | -467 | -177 | -130 | — | — | — | — | — |
| Financing cash flow | -38.3 | -487 | 65.3 | -234 | 27.4 | — | — | — | — | — |
| Share repurchases | -168 | -300 | 0.0 | 0.0 | — | — | — | — | — | — |
| Debt repaid | 0.0 | -309 | 0.0 | -279 | — | — | — | — | — | — |
| Effect of exchange rates | 0.0 | 0.0 | 0.3 | -1.3 | — | — | — | — | — | — |
| Net change in cash | 480 | -18.1 | -11.6 | -73.3 | 154 | — | — | — | — | — |
| Free cash flow | 749 | 557 | 362 | 323 | 233 | — | — | — | — | — |
| Levered free cash flow | 398 | 507 | 439 | 248 | 266 | — | — | — | — | — |